Multiple Sclerosis: THC/CBD Oral Solution

We are studying an oral solution of THC and CBD for people with multiple sclerosis to see if it helps relieve chronic pain and improve other symptoms. This trial compares the treatment to a placebo to assess its effects.

3-6 months 6-10 visits Efficacy phase (II)Post-Trial Drug Access Investigational Medicines OralInternal MedicineNeurology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Cannabidiol

Cannabidiol is a substance that helps reduce seizures and relieve pain, anxiety, and inflammation.

Dronabinol

Dronabinol is a substance that reduces severe nausea from chemotherapy and helps stimulate appetite in people with AIDS-related weight loss.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Placebo

Satalliv

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

CCAB Centro Clinico Academico Braga Associacao

Neurology

Gualtar, Portugal

Sponsor: Ferraz Lynce Especialidades Farmaceuticas S.A.

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.